Tirzepatide (Mounjaro, Zepbound)

Tirzepatide is a synthetic 39-amino acid peptide developed by Eli Lilly that activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. It was approved in 2022 as Mounjaro (type 2 diabetes) and in 2023 as Zepbound (chronic weight management).

The 'dual agonism' is the headline innovation: most earlier drugs hit one of these receptors. Tirzepatide structurally resembles native GIP but has been modified to also activate GLP-1 and to carry a fatty-acid chain that enables once-weekly dosing.^[1]

Tirzepatide originated in Eli Lilly's incretin co-agonism program, which built on years of academic and industrial work suggesting that combining GIP and GLP-1 activity in a single molecule might deliver weight loss beyond what either alone could achieve. The compound (originally LY3298176) was first published in 2018 (Coskun et al., Mol Metab) with structural choices that retained GIP-style binding while adding GLP-1 activity through targeted residue substitutions and a C20 fatty-diacid for albumin-mediated half-life extension.

It received FDA approval as Mounjaro for type 2 diabetes in 2022 and as Zepbound for chronic weight management in 2023. The SURMOUNT and SURPASS Phase 3 programs together comprise one of the largest contemporary pharmacology trial portfolios.

GLP-1 agonism contributes familiar effects — slowed gastric emptying, central appetite suppression, glucose-dependent insulin secretion. GIP agonism adds several pieces that appear to amplify weight loss:

• Increased insulin sensitivity in adipose tissue
• Synergistic effects on central appetite and energy expenditure pathways
• Improved lipid handling

The GIP contribution is still being characterized — the field initially assumed GIP might promote weight gain, but in the context of simultaneous GLP-1 agonism, the net effect in humans is strong additional weight loss.^[2]

Tirzepatide is administered once weekly by subcutaneous injection. Steady state is reached after roughly four weeks. Like semaglutide, half-life extension is achieved through albumin binding via the fatty diacid moiety, but tirzepatide's somewhat shorter half-life (~5 days) reflects different binding kinetics. Bioavailability after subcutaneous administration approaches 80%.

The standard titration begins at 2.5 mg weekly and increases in 2.5 mg increments at four-week intervals up to a maximum of 15 mg. As with other incretins, slower titration is associated with better gastrointestinal tolerability.

The peer-reviewed literature on Tirzepatide is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).

This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.

In trials, tirzepatide is administered as a once-weekly subcutaneous injection with a gradual dose titration (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg). Titration moderates GI side effects.

This page is descriptive of trial protocols, not a usage guide.

Tirzepatide currently sets the clinical benchmark for pharmacologic weight loss — its 20%+ average loss in SURMOUNT-1 is comparable to outcomes once exclusive to bariatric surgery. As a co-agonist, it has expanded what the field believes is possible without surgery and has accelerated interest in triple-agonist successors like retatrutide.

Its safety profile is broadly similar to semaglutide, with the same nuances around muscle preservation, GI titration, and the expectation of weight regain after discontinuation. Cardiovascular outcomes data (SURPASS-CVOT) is still pending, which is the largest remaining gap relative to semaglutide's evidence base.

For most readers, the practical question is no longer whether tirzepatide works but how to access it — Zepbound versus Mounjaro labeling, payer coverage, and the still-evolving compounded landscape — and how to use it as one component of a thoughtful long-term plan.